Protagonist Therapeutics (PTGX) has attracted investor interest after its stock surged by 7.1%, driven by optimism surrounding pipeline milestones and recent FDA developments for rusfertide and Icotyde. With a current share price of $140.07, PTGX has experienced a remarkable 42.88% gain over the past month and an impressive 167.87% return over the last year, indicating reassessment of its growth prospects.
Despite a high price-to-book (P/B) ratio of 13.7x—seen as favorable compared to its peers but steep compared to the broader biotech sector—concerns remain about potential clinical and regulatory hurdles. A discounted cash flow model suggests the stock is undervalued, trading at a significant discount to an estimated fair value of $412.22, hinting at market hesitance regarding execution risks. Investors are encouraged to weigh these risks and monitor further developments in Protagonist’s pipeline.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ptgx/protagonist-therapeutics/news/protagonist-therapeutics-ptgx-could-be-66-below-fair-value-a
